Metraipolis › archive › dc_7d7447fb77b6
Montelukast as a novel therapeutic approach in metastatic uveal melanoma harboring a CYSLTR2 mutation: a translational case report — Europe PMC PMID:41353847
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41353847
- DOI
- 10.1016/j.esmoop.2025.105921
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T21:22:45.312Z
- SHA-256 of the archived text
6f729fa7f8822f868d15aa62aa114bf91a2561f88e1fc296e3e091a76f5644a2- Stable URL of this page
https://metraipolis.com/documento/dc_7d7447fb77b6
How to cite
Montelukast as a novel therapeutic approach in metastatic uveal melanoma harboring a CYSLTR2 mutation: a translational case report — Europe PMC PMID:41353847 — Europe PMC (en), https://europepmc.org/article/MED/41353847 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7d7447fb77b6 (Metraipolis archive dc_7d7447fb77b6, sha256 6f729fa7f8822f868d15aa62aa114bf91a2561f88e1fc296e3e091a76f5644a2)
BibTeX
@misc{dc7d7447fb77b6,
title = {Montelukast as a novel therapeutic approach in metastatic uveal melanoma harboring a CYSLTR2 mutation: a translational case report — Europe PMC PMID:41353847},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41353847},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7d7447fb77b6; sha256 6f729fa7f8822f868d15aa62aa114bf91a2561f88e1fc296e3e091a76f5644a2},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41353847. Agents can read the archived copy with the MCP tool read_document.